Compare · ARGX vs INKT
ARGX vs INKT
Side-by-side comparison of argenx SE (ARGX) and MiNK Therapeutics Inc. (INKT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and INKT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 1035.4x INKT ($50.7M).
- Over the past year, ARGX is down 2.8% and INKT is down 27.8% - ARGX leads by 25.0 points.
- ARGX has been more active in the news (6 items in the past 4 weeks vs 4 for INKT).
- ARGX has more recent analyst coverage (25 ratings vs 8 for INKT).
- Company
- argenx SE
- MiNK Therapeutics Inc.
- Price
- $819.19-3.28%
- $10.82-6.03%
- Market cap
- $52.52B
- $50.7M
- 1M return
- -17.73%
- -13.62%
- 1Y return
- -2.77%
- -27.76%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 8
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
MiNK Therapeutics Inc.
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest INKT
- SEC Form 4 filed by MiNK Therapeutics Inc.
- SEC Form 144 filed by MiNK Therapeutics Inc.
- MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
- MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
- Director Wiinberg Ulf was granted 1,279 shares, increasing direct ownership by 6% to 23,929 units (SEC Form 4)
- Director Behner Peter was granted 1,485 shares, increasing direct ownership by 6% to 24,404 units (SEC Form 4)
- Director Holcomb John Bradley was granted 1,233 shares, increasing direct ownership by 36% to 4,691 units (SEC Form 4)
- Director Ryan Barbara was granted 1,622 shares, increasing direct ownership by 7% to 23,591 units (SEC Form 4)
- Director Corvese Brian was granted 1,633 shares, increasing direct ownership by 3% to 54,770 units (SEC Form 4)
- SEC Form S-8 filed by MiNK Therapeutics Inc.